Lactoferrin is a multifunctional glycoprotein with therapeutic potential for bone tissue engineering. The aim of this study was to assess the efficacy of local application of lactoferrin on bone regeneration. Five-millimetre critical-sized defects were created over the right parietal bone in 64 Sprague-Dawley rats. The rats were randomized into four groups: group 1 (n = 20) had empty defects; group 2 (n = 20) had defects grafted with collagen gels (3 mg/ml); group 3 (n = 20) had defects grafted with collagen gels impregnated with bovine lactoferrin (10 μg/gel); and group 4 (n = 4) had sham surgeries (skin and periosteal incisions only). The rats were sacrificed at 4 or 12 weeks post-operatively, and the calvaria were excised and evaluated with micro-CT (Skyscan 1172) followed by histology. The bone volume fraction (BV/TV) was higher in lactoferrin-treated animals at both timepoints, with groups 1, 2, 3 and 4 measuring 10.5 ± 1.1%, 8.6 ± 1.4%, 16.5 ± 0.6% and 24.27 ± 2.6%, respectively, at 4 weeks (P < 0.05); and 12.2 ± 1.3%, 13.6 ± 1.5%, 21.9 ± 1.2% and 29.3 ± 0.8%, respectively, at 12 weeks (P < 0.05). Histological analysis revealed that the newly formed bone within the calvarial defects of all groups was a mixture of woven and lamellar bone, with more bone in the group treated with lactoferrin at both timepoints. Our study demonstrated that local application of lactoferrin significantly increased bone regeneration in a rat critical-sized calvarial defect model. The profound effect of lactoferrin on bone regeneration has therapeutic potential to improve the poor clinical outcomes associated with bony non-union. LF In Vivo JTERM Authors Contributions.
Introduction
Bone grafting is one of the most common surgical procedures performed worldwide, and its indications range from reconstructive orthopaedic and maxillofacial surgery to spinal fusions. Globally, over two million bone grafting procedures are performed annually, and this number is projected to increase exponentially as a result of population aging (Brounts et al., 2013; Giannoudis et al., 2005) .
Clinically, autologous bone remains the 'gold standard' graft choice for bone grafting. Whilst effective, the amount of autologous bone that can be safely harvested is limited, and the procedure can be associated with unacceptably high complication rates and donor site morbidity (Almaiman et al., 2013; Scheerlinck et al., 2013; Vura et al., 2013) . Alternative graft choices, including allografts, xenografts and synthetic bone graft substitutes, have failed to perform as well as autologous bone graft. In addition, the use of allografts and xenografts can be limited due to the risk of disease transmission and foreign body responses (Shegarfi and Reikeras, 2009) . In recent years, commercial forms of recombinant bone morphogenetic protein (rhBMP) have shown clinical efficacy, and are available for specific clinical applications including spinal fusions and treatment of long bone non-unions (Kanakaris et al., 2008; Malham et al., 2015; Papanna et al., 2012) . However, serious adverse effects and safety concerns have been reported in relation to the use of rhBMP, and its high cost can be prohibitive for widespread clinical use (Carragee et al., 2011; Comer et al., 2012; Epstein, 2013) . Due to the intrinsic limitations associated with currently available bone grafting options, and the rising incidence of bony defects that exceeds the body's regenerative capabilities, the need to find improved bone graft materials has never been greater.
Lactoferrin, belonging to the transferrin family, is an iron-binding glycoprotein present in milk, as well as other bodily secretions. This multifunctional glycoprotein plays a pivotal role in a range of biological processes, and has anti-microbial, anti-neoplastic, anti-inflammatory and immunomodulatory activities (Amini and Nair, 2011; Gonzalez-Chavez et al., 2009; Vogel, 2012) . Furthermore, lactoferrin has been found to be a potent anabolic factor for bone growth. In vitro, lactoferrin dose-dependently enhances the proliferation and differentiation of boneforming cells (osteoblasts), and potently inhibits the formation of bone-resorbing cells (osteoclasts; Cornish et al., 2004) . While in vivo, local injection of lactoferrin over the calvarium of mice resulted in a profound increase in bone formation compared with vehicle controls (Cornish et al., 2004) . However, from a tissue engineering point of view, the effect of local application of lactoferrin on bone regeneration remains unclear. To our knowledge, only three studies have investigated the effect of local application of lactoferrin on bone regeneration. All three studies utilized calvarial defect models, with varying degrees of success. In both rat and pig calvarial defects, lactoferrin increased bone regeneration (Gormez et al., 2015; Takaoka et al., 2011 ), yet in a rabbit calvarial defect model, augmentation of a bovine bone graft (Bio-Oss) with lactoferrin did not result in any significant improvement in bone regeneration (Paknejad et al., 2012) .
Given the limited and inconsistent evidence on the effect of local application of lactoferrin for bone regeneration, we designed this study to further evaluate the effect of local application of lactoferrin on bone regeneration using a rat critical-sized calvarial defect model. We hypothesized that local application of lactoferrin leads to increased bone regeneration.
Materials and Methods
Collagen/lactoferrin gel preparation.
Collagen gels (100 μl) were prepared in a sterile fashion in a tissue culture hood by neutralizing sterile rat collagen type I (In Vitro Technology, Auckland, New Zealand) with 2.3 μl of 1 M NaOH. The gels were diluted to a final concentration of 3 mg/ml using phosphatebuffered saline. The gels were allowed to set at 37°C for at least an hour before surgical implantation into the calvarial defects. Matthews et al. have previously utilized this type of collagen gel to assess its effect on osteoblastogenesis. In their study, the collagen gels remained intact after 24 days of culture (Matthews et al., 2014) . In vivo, the degradation time of the type of collagen gels used in our study is unclear. For preparation of lactoferrin-impregnated collagen gels, bovine lactoferrin (Fonterra Co-operative Group, New Zealand) was incorporated into the 100 μl collagen gels at a concentration of 100 μg/ml. The bovine lactoferrin was thoroughly mixed with the collagen gel by pipetting the solution up and down 10 times. The gels were allowed to set at 37°C for at least an hour before surgical implantation into the calvarial defects.
Surgical procedure
Ethical approval was obtained from the University of Auckland Animal Ethics Committee. In total, 64 sexually mature, similarly aged, male Sprague-Dawley rats weighing more than 250 g were bred for this study. Preoperatively, the rats were checked for general health, weighed and randomized into four groups.
Empty defects (n = 20): 5-mm, bi-cortical, extra-dural defect created over the right parietal bone and left empty.
Collagen carrier group (n = 20): 5-mm, bi-cortical, extra-dural defect created over the right parietal bone, which was grafted with a collagen gel (3 mg/ml).
Lactoferrin-treated group (n = 20): 5-mm, bi-cortical, extra-dural defect created over the right parietal bone, which was grafted with a collagen gel impregnated with bovine lactoferrin (10 μg/gel).
Sham surgery (n = 4): midline incision through skin and periosteum down to parietal bone without creation of a bony defect.
Two hours prior to surgery, the rats were pre-medicated with a subcutaneous injection of a non-steroidal antiinflammatory analgesic, carprofen (10 μl/g; Norbrook, New Zealand). Anaesthetic induction was performed in a rat induction box with continuous isoflurane, and anaesthesia was maintained through a specialized nose cone (5% isoflurane with 2 l oxygen for induction and 2.5% isoflurane with 2 l oxygen for maintenance). A 2.5-ml subcutaneous injection of normal saline was administered immediately following induction to account for fluid losses during surgery.
Once the rats were appropriately anaesthetized, they were placed prone with the calvaria shaved and disinfected with 2% chlorhexidine and 70% ethanol (NZHealthe, New Zealand). The surgical area was draped using OpSite Incise Drape (Smith&Nephew, New Zealand). An incision centred over the sagittal suture was made down to the periosteum. The periosteum was divided in line with the skin incision and elevated as a single flap. A 5-mm-diameter, bicortical, extra-dural defect was created over the right parietal bone using a trephine burr (Komet Trephine, HenrySchein, New Zealand) attached to a hand-held dental drill (Saeshin Thumb Set & Mini Contra Angle Hand Piece, HenrySchein, New Zealand). The dental drill was set at 10 000 revolutions per minute (RPM) and the trephine tip was cooled with normal saline flushes during the burring process. The periosteal flap was then reflected over the defects and sutured to the contralateral side using a 4/0 Monocryl suture (Amtech Medical, New Zealand). The periosteal flap functioned as an envelope to contain the implants (Figure 1) . The skin was then closed using continuous subcuticular 4/0 Monocryl sutures (Amtech Medical, New Zealand). Following skin closure, 0.2 ml of marcain (1.25 mg/ml solution) was infiltrated around the surgical site for post-operative analgesia (Amtech Medical, New Zealand).
Post-operatively, the rats were housed singularly and transferred to a warming cabinet overnight for recovery.
Carprofen (10 μl/g) and normal saline (2 ml) were administered subcutaneously twice daily for 48 h postoperatively for analgesia and fluid replacement. The rats were weighed daily and monitored for signs of illness, infection, pain or distress twice daily for the first two post-operative days. Following this, they were weighed and checked daily until post-operative day 7. They were then weighed and monitored on a weekly basis.
Tissue processing
At the end of the experimental procedures, the rats were euthanised with CO 2 inhalation. The calvaria containing both the parietal lobes and parts of the frontal and occipital lobes were excised. The calvaria were immediately fixed in 10% neutral buffered formalin and stored at 4°C. After 3 days, the calvaria were transferred to 70% ethanol for storage at 4°C until analysis by micro-CT.
Micro-CT
All the specimens were scanned using a Skyscan 1172 micro-CT scanner (X-ray voltage 50 kV, 1.0 mm aluminium filter, isotropic voxel size 12 μm). After standardized reconstruction using NRecon software, the datasets were analysed using CTAn software (Bruker micro-CT, Belgium). To quantitatively evaluate newly formed bone, a cylindrical volume of interest with a diameter of 5 mm and a height of 2.196 mm was concentrically positioned over the defect site in the axial plane. Outcome measures included the bone volume fraction (BV/TV) and tissue mineral density (TMD).
Histology
Following micro-CT, the specimens were decalcified using 10% formic acid for 1 week. After decalcification, the specimens were paraffin embedded in a Leica APS 300S auto processor. Histological sections (10 μm in thickness) were prepared from the mid-point of the defects in the coronal plane using a Leica Microtome RM 2145. Two sections per sample were placed on Leica ApexTM Superior adhesive slides and stained with haematoxylin and eosin (H&E). Digital images of the stained sections were obtained using the Olympus BX50F microscope with an Olympus DP72 digital colour camera (Olympus, Japan). All the H&E-stained sections were evaluated by a blinded musculoskeletal pathologist.
Statistical analysis
All data were statistically analysed by analysis of variance (ANOVA) with post hoc Tukey's test, and expressed as mean ± standard error of the mean (SEM). Graph pad prism 6 software (Graph pad software, USA) was used for statistical analysis.
Results
Two lactoferrin-treated specimens from the 4-week cohort were excluded from analysis. One rat died on the third post-operative day due to bowel obstruction and the other specimen was excluded due to damage to the calvarial bone during tissue excision. All other animals tolerated the procedure well and made satisfactory progress postoperatively. There was no evidence of local or systemic infection in any of the animals throughout the perioperative period.
Micro-CT results
At the 4-week timepoint, bone regeneration, as measured by the bone volume fraction (BV/TV), was significantly higher in the lactoferrin-treated animals (16.5 ± 0.6%) compared with group 1 (10.5 ± 1.1%) and group 2 (8.6 ± 1.4%; P < 0.05). By the 12 week post-operative mark, the bone volume fraction increased in all four experimental groups compared with the 4-week timepoint (Figure 2) . However, the increase was much more profound in the lactoferrin-treated group (21.9 ± 1.2%) compared with group 1 (12.2 ± 1.3%) and group 2 (13.6 ± 1.5%; P < 0.05). The animals in group 4 (sham surgeries) had the highest BV/TV compared with the other three groups at both 4 weeks (24.27 ± 2.6%) and 12 weeks (29.3 ± 0.8%). There was no difference in TMD between the groups at either the 4 or 12 week post-operative mark. 
Histology
Histological assessment by a musculoskeletal pathologist blinded to the treatment groups revealed that there was no evidence of residual gels or infection in any of the specimens, nor was there excessive presence of inflammatory cells in any of the specimens at both timepoints.
In keeping with the micro-CT findings, the lactoferrintreated group had greater amounts of regenerated bone at both 4 and 12 weeks ( Figure 3A) . At higher magnification, large amounts of fibrous tissue were seen in the empty defect and collagen-treated groups. A mixture of lamellar and woven bone were identified without any differences in the types of bone formed between the three groups at both timepoints ( Figure 3B ).
Discussion
Here, we have shown that local application of lactoferrin significantly improved bone regeneration in a rat criticalsized calvarial defect model. This study represents the largest in vivo study evaluating the role of local application of lactoferrin as an anabolic growth factor in the context of bone regeneration. . Treatment groups include empty defects (left); defects treated with a 100 μl collagen gel (3 mg/ml; middle); and defects treated with a 100 μl collagen gel containing bovine lactoferrin (10 μg; right)
Using micro-CT, the bone volume fractions (BV/TV) in all three groups were able to be quantified, and the results demonstrated a profound increase in bone regeneration in response to targeted, local lactoferrin treatment at both the early (4 week) and late (12 week) timepoints. The increase in bone volume fraction in the lactoferrin group was not accompanied by any increase in TMD, suggesting that the degrees of mineralization of newly formed bone were similar between the three goups (Bouxsein et al., 2010) . Microscopically, increased bone regeneration was observed in the group treated with lactoferrin compared with the other two groups. Evidence of remodelling was seen in the form of a mixture of lamellar and woven bone in all treatment groups at both timepoints. There was no difference between the groups in terms of the types of bone formed or the degree of inflammation, suggesting that the anabolic effect of lactoferrin was unlikely to be related to its well-known immune modulatory properties (Adlerova et al., 2008; Gonzalez-Chavez et al., 2009; Malet et al., 2011; Vogel, 2012) .
The role of lactoferrin as an anabolic agent for bone health was first published over a decade ago (Cornish et al., 2004) . In this study, the positive effect of lactoferrin on bone health was attributed, at least in part, to the synergistic ability of this molecule to enhance the survival and differentiation of osteoblasts and inhibit osteoclastogenesis (Cornish et al., 2004) . In the ensuing period, a number of studies have investigated the mechanism through which lactoferrin functions to improve bone healing and regeneration. At a molecular level, the anabolic effect of lactoferrin on bone regeneration has been attributed to its mitogenic effect on host osteoblasts, an effect mediated through the lowdensity lipoprotein receptor-related protein-1 (LRP1) and activation of p42/44 mitogen-activated protein kinase (MAPK) signalling and the PI3-kinase-dependent phosphorylation of Akt in osteoblasts (Cornish et al., 2006; Grey et al., 2004; Naot et al., 2011) .
From an osteoporosis point of view, a number of in vivo studies have reiterated the beneficial role of lactoferrin on systemic bone health in osteoporotic animal models. should encourage future studies utilizing more clinically relevant, load-bearing models such as spinal fusion and long bone defect models. Future studies should focus on delineating the mechanisms by which lactoferrin functions to increase bone regeneration in vivo.
In conclusion, this study demonstrated that local application of lactoferrin significantly increased bone regeneration in a rat critical-sized calvarial defect model. The profound anabolic effect of lactoferrin was evident as early as 4 weeks and persisted until 12 weeks postimplantation. The additional putative roles of lactoferrin as an anti-microbial, anti-inflammatory and immunomodulatory agent make this naturally occurring glycoprotein an attractive growth factor for bone regeneration. 
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